BioDlink International Company Limited (HKG:1875)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.200
0.00 (0.00%)
At close: Feb 13, 2026
Market Cap3.25B +133.3%
Revenue (ttm)1.17B +9.6%
Net Income7.96M -19.0%
EPS0.01 -19.0%
Shares Out772.79M
PE Ratio407.99
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,898,700
Average Volume3,431,340
Open4.200
Previous Close4.200
Day's Range4.170 - 4.200
52-Week Range1.520 - 4.660
Beta0.22
RSI73.69
Earnings DateMar 11, 2026

About HKG:1875

BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 604
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1875
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements